ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
69,278.56
2.26%
S&P 500
5,277.51
0.80%
Dow Jones
38,686.32
1.51%
US Dollar vs Yen
157.1035
-0.05%
Brent Oil
81.18
0.46%
Registration Strip Icon for discussion 登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Gilead Sciences Inc (GILD)

  7. Gilead Sciences Inc (GILD) ニュース

GILD

Gilead Sciences (GILD)

Gilead Sciences Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:GILD
日付受信時刻ニュースソース見出しコード企業名
2024/06/0221 : 00Business WireGilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal CancerNASDAQ:GILDGilead Sciences Inc
2024/06/0221 : 00Business WireGilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal CancerNASDAQ:GILDGilead Sciences Inc
2024/06/0121 : 00Business WireGilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI CancersNASDAQ:GILDGilead Sciences Inc
2024/06/0121 : 00Business WireGilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI CancersNASDAQ:GILDGilead Sciences Inc
2024/05/3121 : 07Business WireEVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024NASDAQ:GILDGilead Sciences Inc
2024/05/3105 : 45Business WireGilead Provides Update on Phase 3 TROPiCS-04 StudyNASDAQ:GILDGilead Sciences Inc
2024/05/2221 : 30Business WireGilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024NASDAQ:GILDGilead Sciences Inc
2024/05/1821 : 30Business WireInvestigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary CholangitisNASDAQ:GILDGilead Sciences Inc
2024/05/1423 : 09Business WireKite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell TherapyNASDAQ:GILDGilead Sciences Inc
2024/05/1006 : 57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
2024/05/1006 : 30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
2024/05/1006 : 26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
2024/05/1006 : 23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
2024/05/1006 : 16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
2024/05/1006 : 08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
2024/05/1005 : 11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GILDGilead Sciences Inc
2024/05/1005 : 05Business WireKite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma ProgramNASDAQ:GILDGilead Sciences Inc
2024/05/1004 : 46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
2024/05/1004 : 38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
2024/05/0905 : 58Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GILDGilead Sciences Inc
2024/05/0721 : 30Business WireGilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024NASDAQ:GILDGilead Sciences Inc
2024/05/0105 : 05Business WireGilead Sciences to Present at Upcoming Investor ConferencesNASDAQ:GILDGilead Sciences Inc
2024/04/2621 : 00Business WireFDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIVNASDAQ:GILDGilead Sciences Inc
2024/04/2620 : 47IH Market NewsExxon Mobil Net Profit Drops 28% to $8.22 Billion, Atlassian Surprises with Revenue Boost and Co-CEO Exit, and More in EarningsNASDAQ:GILDGilead Sciences Inc
2024/04/2605 : 02Business WireGilead Sciences Announces First Quarter 2024 Financial ResultsNASDAQ:GILDGilead Sciences Inc
2024/04/2520 : 53IH Market NewsU.S. Futures Drop in Pre-Market Trading as Tech Stocks Plunge After Meta Issues Gloomy ForecastNASDAQ:GILDGilead Sciences Inc
2024/04/0905 : 05Business WireGilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024NASDAQ:GILDGilead Sciences Inc
2024/03/2821 : 30Business WireFDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as SixNASDAQ:GILDGilead Sciences Inc
2024/03/2820 : 00Business WireGilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 ProgramNASDAQ:GILDGilead Sciences Inc
2024/03/2820 : 00GlobeNewswire Inc.Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 ProgramNASDAQ:GILDGilead Sciences Inc
 Showing the most relevant articles for your search:NASDAQ:GILD

最近閲覧した銘柄

COIN
ORLYGBP
EU
FRSG00014RF4
SG Issuer Sg Issuer Mc M...
EU
MEMS
Memscap
EU
HSBCK
HSBC Bank France 1.115% ...
LSE
ZT88
Int.fin. 27
LSE
BAP
USOTC
BBLS
Petrolia Energy (CE)
NYSE
AXP
American Express
NYSE
RONI
Rice Acquisition Corp II
LSE
51OX
Stan.ch.bk.frn
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有